DES and programmed surgery: reality or myth

Original title: Drug-Eluting Stents versus Bare Metal Stents Prior to Noncardiac Surgery. Reference: Sripal Bangalore, et al. Catheterization and Cardiovascular Intervention 2015;85:533-41

Drug eluting stents (DES) have proved beneficial compared to bare metal stents (BMS), but the need to program a surgical procedure after a percutaneous coronary intervention (PCI) has limited its use.

This study analyzed patients receiving PCI and non cardiac surgery (NCS) between April 2004 and September 2007. It included 8415 patients, 6538 (78%) receiving DES and 1877 BMS.

After propensity score matching was applied to adjust for differences, 5403 patients remained for final analysis, 3565 (66%) receiving DES and 1838 (34%) BMS. Primary end point was net clinical outcome at 30 days, a combination of death, infarction or bleeding.  

Population mean age was 69, 37% were diabetic, 20% had had previous revascualrization surgery, 23% previous PCI procedures and 43% had renal failure or were on dialysis.

In the DES cohort, the net clinical end point saw a reduction at 30 days, with longer time from PCI to NCS (p=0,02). The best outcome was obtained when surgery was performed after 90 days of PCI (event rate of 8.57, 7.53, 5.21, and 5.75% for 1-30, 31-90, 91-180 and 181-365 days, respectively, from PCI to NCS).

However, in the BMS cohort event rate was uniform and high, regardless PCI to NCS time (event rate of 8.20, 6.56, 8.05, and 8.82% for 1-30, 31-90, 91-180 and 181-365 days, respectively, from PCI to NCS. Finally, a marginal tendency to more bleeding was observed in the DES group. 

Conclusion

DES stents were not associated to more adverse events after a programmed NCS. Moreover, adverse events incidence was higher when NCS was performed 90 days after PCI, which suggests it is not necessary to wait 12 months after DES stenting to perform an NCS.

Editorial Comment

The need for surgery is relatively rare after PCI; even though the use of BMS is recommended, this retrospective analysis shows that the use of DES is a viable and safe alternative, especially after 90 days. However, we should collect more information and study groups that will benefit most before changing our clinical practices.

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

Carlos Fava

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...